Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …

Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-
SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer …

Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from …

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …

Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is
strongly associated with favorable outcome. We examined the utility of serial circulating …

Background Breast cancer is highly heterogeneous, resulting in different treatment
responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative …

PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease
(RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence …

PURPOSE The achievement of pathologic complete response (pCR) is strongly prognostic
for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer …

Neoadjuvant chemotherapy (NAC) had been developed as a systematic approach before
definitive surgery for the treatment of locally advanced or inoperable breast cancer such as …